Safe and Efficacious Use of a Topical Retinoid Under Occlusion for the Treatment of Mycosis Fungoides

December 2014 | Volume 13 | Issue 12 | Editorials | 1479 | Copyright © December 2014


Daniel Aires MD JD,a Tarek Shaath BS,c Garth Fraga MD,b
Anand Rajpara MD,a Ryan Fischer MD,a Deede Liu MD,a

aUniversity of Kansas Medical Center, Department of Internal Medicine,
Division of Dermatology, Kansas City, KS
bUniversity of Kansas Medical Center, Department of Pathology, Kansas City, KS
cUniversity of Kansas School of Medicine, Kansas City, KS

table 2
steroids under occlusion for treatment of a resistant folliculotropic MF plaque. This may present an alternative for resistant MF. It also points toward the need for further work exploring treatment of MF and other dermatoses with occluded retinoids and steroids.

Disclosures

The authors have no conflicts of interests to declare.

References

  1. Martin AG. Bexarotene gel: A new skin-directed treatment option for cutaneous T-cell lymphomas. J Drugs Dermatol. 2003;2(2):155-167.
  2. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clinical Oncol. 2001;19(9):2456-2471.
  3. Querfeld C, Rosen ST, Guitart J, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol. 2004;51(1):25-32.
  4. Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801-815.
  5. Griffiths CE, Kang S, Ellis CN, et al. Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. A double-blind, vehicle-controlled comparison of 0.1% and 0.025% tretinoin creams. Arch Dermatol. 1995;131(9):1037-1044.
  6. Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. 2004;50(4):600-607.
  7. McMichael AJ, Griffiths CE, Talwar HS, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol. 1996;135(1):60-64.
  8. Stam-Posthuma JJ, Vink J, le Cessie S, Bruijn JA, Bergman W, Pavel S. Effect of topical tretinoin under occlusion on atypical naevi. Melanoma Res. 1998;8(6):539-548.
  9. Watson RE, Craven NM, Kang S, Jones CJ, Kielty CM, Griffiths CE. A short-term screening protocol, using fibrillin-1 as a reporter molecule, for photoaging repair agents. J Invest Dermatol. 2001;116(5):672-678.
  10. Fisher GJ, Wang ZQ, Datta SC, Varani J, Kang S, Voorhees JJ. Pathophysiology of premature skin aging induced by ultraviolet light. New Engl J Med. 1997;337(20):1419-1428.
  11. Zackheim HS. Treatment of cutaneous T-cell lymphoma. Semin Dermatol. 1994;13(3):207-215.
  12. Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin N Amer. 1995;9(5):1031-1056.
  13. Pothiawala SZ, Baldwin BT, Cherpelis BS, Lien MH, Fenske NA. The role of phototherapy in cutaneous T-cell lymphoma. J Drugs Dermatol. 2010;9(7):764-772.
  14. Micaily B, Vonderheid EC, Brady LW, Andrews C. Total skin electron beam and total nodal irradiation for treatment of patients with cutaneous T-cell lymphoma. Inter J Radiat Oncol, Biol, Phys. 1985;11(6):1111-1115.
  15. Hunzeker CM, Fangman W, Latkowski JA. Folliculotropic mycosis fungoides. Dermatol Online J. 2007;13(1):5.
  16. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol. 1992;27(3):427-433.
  17. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109-3115.
  18. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19(2):376-388.

AUTHOR CORRESPONDENCE

Deede Liu MD……................dliu@kumc.edu
Close Menu